Literature DB >> 17250431

ABO blood group frequency and brain tumors.

Masoud Mehrazin1.   

Abstract

The influence of blood group types on development of brain tumors is unclear since there are conflicting reports from surveys regarding the distribution of ABO blood groups and primary intracranial neoplasms. The present descriptive, retrospective study was therefore made of 907 patients with reliable records for ABO blood groups and proven histological diagnosis who were hospitalized with brain tumors at the Shariati Hospital neurosurgical center, between 1980 and2002. The distribution of the ABO blood groups in this study population was compared with that in the general population by the chi-square test. Data analysis showed that there are no significant differences between types of intracranial tumors and frequencies of four major blood groups. The distribution of the ABO blood groups in patients did not differ significantly from that of the general population. Of our patients with craniopharyngioma, however, significantly more were in group A (P<0.05) compared with the general population of Iran.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17250431

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  3 in total

1.  Histopathological Study of Central Nervous System Lesions: Emphasizing Association of Neoplasms with ABO Blood Groups.

Authors:  B N Kumarguru; P Pallavi; G V Manjunath; T S Vasan; B R Rajalakshmi
Journal:  J Clin Diagn Res       Date:  2017-04-01

2.  Evaluation of Organs at Risk's Dose in External Radiotherapy of Brain Tumors.

Authors:  Hamideh Nazemi-Gelyan; Hadi Hasanzadeh; Yasha Makhdumi; Sara Abdollahi; Fatemeh Akbari; Fatemeh Varshoee-Tabrizi; Hamzeh Almasrou; Alireza Nikoofar; Mostafa Rezaei-Tavirani
Journal:  Iran J Cancer Prev       Date:  2015 Jan-Feb

3.  AB Blood Group Confers Higher Risk for Primary Brain Tumors in Pediatrics.

Authors:  Abdulrahman Al Shudifat; Hala Al Suqi; Kutada Soub; Leen Al Nemrawi; Moa'tasem Abu Jaber; Mohammad Al Barbarawi; Nour Shewaikani; Yazan El Adwan; Assem Al Refaei
Journal:  Risk Manag Healthc Policy       Date:  2021-09-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.